News & Updates

Tofacitinib effective in ulcerative colitis, but higher doses lead to adverse events

The overall efficacy and safety of tofacitinib in moderate-to-severe ulcerative colitis (UC) agree with clinical trial data, but a dose-dependent increase in adverse events (AEs) occurs, which underscores the importance of early dose de-escalation, according to a study.

Postpartum cervical length predicts subsequent preterm birth

Postpartum cervical length measurements help pinpoint which patients are at heightened risk of subsequent spontaneous preterm birth, as reported in a study.

Hyperbaric oxygen therapy ineffective in kids with cerebral palsy

There appears to be evidence suggesting that hyperbaric oxygen therapy does not yield motor and cognitive benefits in children with cerebral palsy, a recent study has found.

Association between PFS2 and Immunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC)

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.

Asundexian for secondary prevention after acute MI scores high in early trial

The oral activated factor XI (FXIa) inhibitor asundexian, when taken with aspirin plus a P2Y12 inhibitor, appears to facilitate dose-dependent, near-complete inhibition of FXIa activity with a low rate of ischaemic events and without a significant increase in bleeding, according to the results of a phase II trial.